All In Biotech

Drug Trial Radar · NCT04942067

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis

Last checked: Nov 19, 2026Latest source record: Oct 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

108

Planned (sponsor's estimate)

Start

Dec 23, 2021

Primary completion

Sep 1, 2024

Study completion Dec 1, 2024

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
First posted
Jun 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists of dose escalation and dose expansion phases. The study consists of will start with 2 arms noted below, both arms are independent

Conditions

  • Multiple Myeloma
  • Amyloidosis

Interventions

  • APG-2575+ PdDrug

    APG-2575 + Pomalidomide 4mg QD x 21 days + dexamethasone (40 mg for patients ≤ 75 years old or 20 mg for patients \> 75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle

  • APG-2575 + DRdDrug

    APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg for patients \> 75 years old) once weekly, and daratumumab will be administered intravenously at a dose of 16 mg/kg (or 1800 mg administered subcutaneously if commercially available) weekly in cycles 1 and 2 and then every 2 weeks in cycles 3 to 6 and every 4 weeks thereafter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicityTime frame: 28 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Weil Cornell Medical Center

    New York, New York · Recruiting

  • Cleveland Clinic Hosptials

    Cleveland, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.